Loading...
 
Translate Register Log In Login with facebookLogin and Register

Good Vitamin D receptor reduced bladder cancer and cisplatin deaths – April 2019

Vitamin D3 enhances the response to cisplatin in bladder cancer through VDR and TAp73 signaling crosstalk

Cancer Medicine: 10 April 2019 https://doi.org/10.1002/cam4.2119
Brittany L. Bunch Yingyu Ma Kristopher Attwood Lauren Amable Wei Luo Carl Morrison Khurshid A. Guru Anna Woloszynska‐Read … See all authors

VitaminDWiki

derived from Grassroots 2013
Items in both categories Cancer - Bladder and Vitamin D Receptor are listed here:

Chemotherapy and Cisplatin


Items in both categories Vitamin D Receptor and  Cancer

Vitamin D Receptor had the following - April 2019

Risk
increase
Cancer
4.6Breast Cancer 16.9 X another study
3.1 Colon Cancer survival
2.7Gastric Cancer
2.4Lung Cancer
1.6Prostate Cancer while black


Vitamin D Receptor table shows what compensates for low VDR activation

Compensate for poor VDR by increasing one or more:

IncreasingIncreases
1) Vitamin D supplement
  Sun, Ultraviolet -B
Vitamin D in the blood
and thus in the cells
2) MagnesiumVitamin D in the blood
 AND in the cells
3) Omega-3 Vitamin D in the cells
4) Resveratrol Vitamin D Receptor
5) Intense exercise Vitamin D Receptor
6) Get prescription for VDR activator
   paricalcitol, maxacalcitol?
Vitamin D Receptor
7) Quercetin (flavonoid) Vitamin D Receptor
8) Zinc is in the VDRVitamin D Receptor
9) BoronVitamin D Receptor ?,
etc
10) Essential oils e.g. ginger, curcuminVitamin D Receptor
11) ProgesteroneVitamin D Receptor
12) Infrequent high concentration Vitamin D
Increases the concentration gradient
Vitamin D in the cells

Note: If you are not feeling enough benefit from Vitamin D, you might try increasing VDR activation. You might feel the benefit within days of adding one or more of the above

 Download the PDF from VitaminDWiki

Image

Image

Suspect that >20ng Vitamin D PLUS Good Vitamin D receptor would be even better

Background
Vitamin D3 (VitD) deficiency is linked to increased incidence and worse survival in bladder cancer (BCa). In addition to cystectomy, patients are treated with cisplatin‐based chemotherapy, however 30%‐50% of patients do not benefit from this treatment. The effects of VitD deficiency on response to chemotherapy remain unknown.

Methods
To test effects of VitD supplementation on the response to cisplatin we analyzed patient serum VitD levels and correlated that with survival. In vivo, VitD deficient mice were treated with cisplatin, with or without pretreatment with the active VitD metabolite, 1,25 dihydroxyvitamin D3 (1,25D3). Lastly, using BCa cell lines, T24 and RT‐112, the mechanism of action of 1,25D3 and cisplatin combination treatment was determined by apoptosis assays, as well as western blot and RT‐PCR.

Results
In this study, we determined that low serum 25 hydroxyvitamin D3 (25D3) levels was significantly associated with worse response to cisplatin. Pretreating deficient mice with 1,25D3, reduced tumor volume compared to cisplatin monotherapy. In vitro, 1,25D3 pretreatment increased the apoptotic response to cisplatin. 1,25D3 pretreatment increased expression of TAp73 and its pro‐apoptotic targets, in a VDR dependent manner. VDR and its transcriptional targets were induced after 1,25D3 treatment and further increased after the combination of 1,25D3 and cisplatin in a TAp73 dependent manner.

Conclusions: Our data suggest that VitD deficiency could be a biomarker for poor response to cisplatin, and pretreating with VitD can increase the apoptotic response to cisplatin through VDR and TAp73 signaling crosstalk.

Created by admin. Last Modification: Thursday April 11, 2019 17:10:25 GMT-0000 by admin. (Version 8)

Attached files

ID Name Comment Uploaded Size Downloads
11749 Bladder cancer survival.jpg admin 11 Apr, 2019 16:29 23.45 Kb 92
11748 VDR Cancer.jpg admin 11 Apr, 2019 16:29 23.33 Kb 82
11747 cisplatin in bladder cancer.pdf PDF 2019 admin 11 Apr, 2019 16:22 1,004.29 Kb 42
See any problem with this page? Report it (FINALLY WORKS)